pocketful logo
Bilcare Ltd logo

Bilcare Ltd

NSE: BSE: 526853

57.32

(2.38%)

Tue, 24 Mar 2026, 01:15 am

Bilcare Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    126.25

  • Net Profit

    -56.18

  • P/B

    0.46

  • Sector P/E

    19.54

  • P/E

    0

  • EV/EBITDA

    15.49

  • Debt/Equity (Industry)

    0.28

  • Interest Cover (Industry)

    3.74

  • ROCE (Industry)

    4.97

  • RONW (Industry)

    6.17

  • ROE

    0

  • ROCE

    0

  • Debt/Equity

    1.49

  • EPS (TTM)

    0

  • Dividend Yield

    0

  • Book Value

    192.51

  • Interest Cover

    0.14

Analysis

all

thumbs up icon

Pros

  • Bilcare's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Bilcare's share price is below the future cash flow value, and at a substantial discount (> 40%).
  • 526853 outperformed the Life Sciences industry which returned 36.1% over the past year.
  • 526853 outperformed the Market in India which returned -14.5% over the past year.
  • BSE:526853 is up 70.3% outperforming the Life Sciences industry which returned 2.6% over the past month.
thumbs up icon

Cons

  • Unable to calculate sustainability of dividends as Bilcare has not reported any payouts.
  • Unable to evaluate Bilcare's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Bilcare's dividend against the top 25% market benchmark as the company has not reported any payouts.
  • Bilcare's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Debt is not well covered by operating cash flow (9%, less than 20% of total debt).

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersDEC 2025SEPT 2025JUN 2025MAR 2025DEC 2024
Promoters30.0130.0130.0130.0130.01
FII0.040.040.040.040.04
DII00000
Public69.9469.9469.9469.9469.94
Government00000

Read More

Technical Analysis

RSI

35.81

MACD

-2.52

50 DMA

63.41

200 DMA

76.51

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic88.9875.6066.9462.2253.5648.8435.46
Fibonacci75.6070.4967.3362.2257.1153.9548.84
Camarilla61.9560.7259.5062.2257.0455.8254.59

Pivots Level: Classic

R3

+26.76

88.98

R2

+13.38

75.60

R1

+4.71

66.94

62.22
62.22
Pivot Point
LTP: 53.62

S1

-8.67

53.56

S2

-13.38

48.84

S3

-26.76

35.46

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    56.57

  • 20-EMA

    58.33

  • 30-EMA

    60.16

  • 50-EMA

    63.70

  • 100-EMA

    69.63

  • 200-EMA

    73.06

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
12 Feb 2026board-meetingsQuarterly Results
14 Nov 2025board-meetingsQuarterly Results
03 Sept 2025agm
17 Sept 2024agm
06 Sept 2023agm
04 Mar 2023egm
11 Jul 2022agm
07 Sept 2021agm

Read More

Peer Comparison

Bilcare Ltd logo

Bilcare Ltd

Inox India Ltd logo

Inox India Ltd

AGI Greenpac Ltd logo

AGI Greenpac Ltd

EPL Ltd logo

EPL Ltd

Garware Hi Tech Films Ltd logo

Garware Hi Tech Films Ltd

Uflex Ltd logo

Uflex Ltd

Read More

Bilcare Ltd About

Bilcare is engaged mainly in Pharma Packaging Research Solutions & its products

Industry

Packaging

Founded

1987

Headquarters

CEO

Shreyans Bhandari

Employees

Contact

Website icon

Website

http://www.bilcare.com

Email icon

Email

investors@bilcare.com

Phone icon

Phone

91-02135-304200/204201

Location icon

Location

1028 Shiroli Village, Taluka Khed Rajgurunagar, Pune, Maharashtra, 410505

Read More

Bilcare Ltd Company History

YearHistory
2010
  • Bilcare successfully executed non-ClonableID technology worldwide.
  • Bilcare AG completed the acquisition of INEOS' Global Films Business.
2012
  • Bilcare signed a definitive agreement with United Drug plc.
  • United Drug plc completed the USD 61 million acquisition of Bilcare's US and UK-based Global Clinical Supplies businesses.
2014
  • CS Pawan G. Chandak was appointed as Director of the company.
  • The company received the Frost & Sullivan Global 2014 Award.
  • The company received the CII Industrial Innovation Award.
2015
  • Bilcare was recognized as Admired 100 Brands & Leaders of Asia-2014-15 by VWP World Brands.
2016
  • Bilcare GCS received the ABP News Healthcare award 2015 for best Clinical Trial Services.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
GUTTIKONDA VARA LAKSHMIBuy17534493.4815 Sept 2025
GUTTIKONDA RAJASEKHARBuy12036870.2629 Aug 2025
GUTTIKONDA RAJASEKHARSell275670.3529 Aug 2025
GUTTIKONDA RAJASEKHARBuy14093194.5603 Apr 2025
GUTTIKONDA VARA LAKSHMIBuy13032592.328 Mar 2025
GUTTIKONDA VARA LAKSHMIBuy13958982.6525 Mar 2025
SHAH SHARAD KANAYALALSell21025471.6921 Mar 2025
GUTTIKONDA VARA LAKSHMIBuy21767372.0721 Mar 2025
SHAH SHARAD KANAYALALBuy23100081.4702 Jan 2025
GUTTIKONDA VARA LAKSHMIBuy12156368.6926 Dec 2024

Read More

Bilcare Ltd News

Bilcare Q3FY26 Results: Standalone Profit Surges

Bilcare Limited reports strong Q3FY26 standalone performance with net profit of ₹2.71 crores vs ₹1.80 crores YoY, while consolidated operations face headwinds with ₹12.81 crores loss.

12 Feb 2026

co actions results

Bilcare Limited Reports Mixed Quarterly Performance with Standalone Profit but Consolidated Losses

Bilcare Limited posted standalone net profit of ₹1.04 crores for the quarter ended September 30, 2025, while consolidated operations recorded a net loss of ₹23.32 crores. The company faces ongoing challenges including SFIO investigation, CSIR loan default issues, and auditor concerns about going concern status despite positive outlook for GCS business.

14 Nov 2025

earnings

Bilcare Limited Reports Consolidated Loss of ₹9.76 Crores for Quarter Ended June 30, 2025

Bilcare Limited published its unaudited financial results for the quarter ended June 30, 2025. On a consolidated basis, the company reported total income from operations of ₹192.44 crores compared to ₹197.88 crores in the same quarter last year. The company posted a net loss after tax of ₹9.76 crores, an improvement from the ₹15.02 crores loss in the corresponding quarter of the previous year. Earnings per share stood at ₹(1.59) compared to ₹(2.71) in the same period last year. On a standalone basis, the company showed better performance with total income from operations of ₹8.79 crores and profit after tax of ₹3.59 crores, compared to ₹8.71 crores income and ₹1.40 crores profit in the previous year's quarter. The equity share capital remained unchanged at ₹23.55 crores.

18 Aug 2025

earnings

Bilcare Limited's Statutory Auditor Sharp & Tannan Associates Resigns Due to Resource Constraints

Bilcare Limited announced that Sharp & Tannan Associates, Chartered Accountants, resigned as statutory auditors effective August 14, 2025. The auditor cited resource bandwidth issues due to a regulatory matter requiring more senior-level time than anticipated, making future efforts difficult to estimate reliably. The auditor stated that considering Bilcare's size and scale, the demands on their resources for this engagement were disproportionate. Additionally, Bilcare expressed desire to align the auditor for their major subsidiary with the holding company, which was not feasible for Sharp & Tannan due to bandwidth constraints. The auditor confirmed no concerns relating to financial statements, accounting policies, or governance. Sharp & Tannan had been appointed in September 2023 and completed the audit for the year ended March 31, 2025, and the limited review for the quarter ended June 30, 2025. The firm confirmed full cooperation with the incoming auditor for a smooth transition.

14 Aug 2025

corporate governance

Bilcare Limited Reports Q1 FY2026 Results, Appoints New Auditors and Sets AGM Date

Bilcare Limited's Board approved unaudited financial results for the quarter ended June 30, 2025. The company reported standalone revenue from operations of Rs 2.07 crores compared to Rs 4.87 crores in the same quarter last year, while net profit stood at Rs 3.59 crores versus Rs 1.40 crores previously. On a consolidated basis, revenue from operations was Rs 186.36 crores against Rs 194.14 crores in the prior year quarter, with a net loss of Rs 9.76 crores compared to a loss of Rs 15.02 crores last year. The Board recommended appointing M/s. Ghatpande & Ghatpande Associates as Secretarial Auditors for five years from FY 2025-26 to FY 2029-30, subject to shareholder approval. The company scheduled its 38th Annual General Meeting for September 24, 2025. The auditors noted material uncertainty regarding the company's going concern status due to past operating losses, though management expects positive prospects for the GCS business.

14 Aug 2025

earnings

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800